- LinKinvax, a biotech start-up founded in 2020
- Development of a vaccine platform that is unique in its mechanism of action and adaptable to several infectious agents.
- An HIV vaccine currently in clinical trials and two others due to enter trials by 2022: against Papillomavirus-related cancers and SARS-CoV-2.
- €31 million in public funding to accelerate the development of the SARS-CoV-2 vaccine.
A breakthrough in vaccines development to target each virus or variant
LinKinVax is developing a vaccine platform based on academic research conducted by the Vaccine Research Institute Laboratory of Excellence created in 2011 by Université Paris Est Créteil and ANRS/INSERM. This platform targets dendritic cells, which activate our adaptive immune system.
LinKinVax’s technology enables the acceleration of prophylactic and therapeutic vaccine development, ready to address new pathogens and their variants, to improve or to boost first-generation vaccines.
Protein vaccines: a safe and efficient technology
LinKinVax’s mature pipeline results from the use of a proven technology: protein vaccines. This type of vaccine has been used for more than 30 years with excellent medical and economic results. The production process is reliable ensuring predicable quality, volume, and price of supply.
An ongoing first phase 1 clinical trial in 2021, two more planned for 2022
LinKinVax has a particularly mature pipeline with three vaccines in or ready to enter clinical trials: a prophylactic HIV vaccine currently in Phase 1, a multi-epitope and multi-variant SARS-CoV-2 vaccine in 2022, and an HPV cancer vaccine expected to be approved for Phase 1 and 2 trials in 2022. LinKinvax’s goal is to develop five vaccines for commercialization within the next five years.
Strong market prospects
LinKinVax has strong assets to become a leading player in a $35 billion market with 10% annual growth: proven public support, with €31 million in public funding; a protected portfolio of 13 patent families; and an experienced management team combining medical and industrial expertise around co-founders André-Jacques Auberton-Hervé and Yves Lévy, cumulating more than 30 years at the forefront of the semiconductor industry and medical research. LinKinVax combines scientific and industrial excellence to ensure rapid and sustainable development. Entry of entry several products from the same platform into clinical development will accelerate industrial partnerships and funding to bring products to market quickly.
Press contact
LinKinVax : Kathleen ANDRE – kandre@equancy.com – +33 6 16 55 43 05
About LinKinVax
LinKinVax is developing a unique and innovative vaccine platform to boost the delivery of safe, effective and scalable vaccines. Based on the work of the Vaccine Research Institute (VRI), a French laboratory of excellence created in 2011, this DC-Targeting vaccine platform is universal and adaptable to mutations in targeted pathogens. The first five vaccines are expected on the market within five years, including a vaccine already in clinical trials for HIV in 2021, and two vaccines that will be in clinical phase in 2022 (SARS-COV-2, HPV-related cancer). LinKinVax also supports Discovery Research to adapt its platform to new pathogens.
Born out of the meeting of leading French scientists and entrepreneurs, LinKinVax benefits from a unique patent portfolio of 13 families extended internationally and close ties with the Vaccine Research Institute Excellence Laboratory.
For more information, visit www.linkinvax.com